Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 92.8%

Neg 0% Neu 0% Pos 92.8%

Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $20 to $30.